Fierce Pharma

FDA rejects Hengrui, Elevar’s PD-1 liver cancer combo for a 3rd time

The third time is not the charm for Hengrui Pharma and Elevar Therapeutics’ star-crossed combination of camrelizumab and ...
Yicai Global

China’s Hengrui Pharma Is Hit by Third Delay in US Approval for Liver Cancer Drug

China’s Hengrui Pharmaceuticals has announced a third delay in US approval for its liver cancer therapy, due to the need for ...
Hosted on MSN

Injecting PD-1 drug directly into oral precancers shrinks lesions

SAN DIEGO -- Injecting the PD-1 inhibitor nivolumab (Opdivo) directly into high-risk oral precancers proved safe and reduced lesion size in the vast majority of patients enrolled in a small phase I ...

CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody) ASCO 2026 Key Highlights

The clinical datasets presented at ASCO 2026 by CStone further validate the trispecific synergistic mechanism of CS2009 and support it ...
WBOC

Junshi Biosciences Presents Results from JS207 (PD-1/VEGF BsAb) Phase 2 Combo Studies and JS212 (EGFR/HER3 ADC) FIH Phase 1/2 Study at AACR 2026

SHANGHAI, April 20, 2026 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the ...

European Commission Approves Trodelvy® as a First-Line Treatment for Metastatic Triple-Negative Breast Cancer Patients Not Candidates for PD-(l)1 Inhibitors

(Nasdaq: GILD) today announced that the European Commission (EC) has granted marketing authorization for Trodelvy ® (sacituzumab govitecan-hziy) as monotherapy for the treatment of adult patients with ...